Hudson Bay Capital Management LP Nektar Therapeutics Call Options Transaction History

Hudson Bay Capital Management LP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 12, 2022	SELL	$3.17 - $6.17 $158,500 - $308,500	-50,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $82,784 - $273,028	19,900 Added 66.11%	50,000 $270,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $325,983 - $554,141	30,100 New	30,100 $407,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.